Baycip
Developed to mitigate deep-seated bacterial colonisations to support structural clearance and target bacterial topoisomerase.
- Categories
- Antibiotics · Respiratory Health · Bladder Health
- Active ingredient
- Ciprofloxacin
- Route
- Oral use
- Form
- Tablet
- Strengths
- 500mg
Prescription and consultation requirements for Baycip vary by destination and are determined by the fulfilment partner.
Baycip details
- Alternative names
- ciprofloxacin
- Therapeutic class
- Fluoroquinolone
- Pharmacological class
- Fluoroquinolone Antibiotic
- Contraindications
- concurrent tizanidine use; hypersensitivity to ciprofloxacin
- Minor side effects
- nausea; diarrhoea; vomiting
- Moderate side effects
- dizziness; insomnia; rash
- Dosage forms
- Tablet
- Administration route
- Oral use
- Supply category
- Prescription-only medicine (POM)
- Manufacturer
- Cipla Ltd
- Onset Time
- 1–2 hours
- Duration
- 12 hours
- Storage instructions
- Store below 25°C.
- Drug interactions
- Theophylline; Antacids; Tizanidine
- Age restrictions
- Approved for paediatric and adult patients.
Serious side effects
tendonitis and tendon rupture, requires immediate medical attention; peripheral neuropathy, requires immediate medical attention
Patient summary
developed to mitigate deep-seated bacterial colonisations to support structural clearance and target bacterial topoisomerase.
Mechanism of action
Inhibits DNA gyrase and topoisomerase IV, breaking bacterial chromosomes and causing rapid structural cell death.
Pregnancy and breastfeeding
TGA Category C: Potential risk to arthropathy. Avoid if possible. Breastfeeding: Consult a doctor.